Science Publications

Treatments for Inflammation Publications

Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19)

The results of the Phase II trial provided first-ever evidence validating Dipeptidase-1 (DPEP1) as a mediator of organ inflammation and therapeutic target in humans. In addition, LSALT peptide was well tolerated with no safety issues related to the drug.

The Phase II trial was an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide for the prevention of organ inflammation such as acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) in hospitalised patients infected with SARS-CoV-2. The exploratory, adaptive trial was initiated in the early stages of the global pandemic to ...

Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury

Importantly, the study also confirmed the mechanism of action of two DPEP-1 inhibitors, the LSALT peptide (Metablok) and cilastatin that effectively protected the kidney during ischemia reperfusion injury. Both the LSALT peptide and cilastatin are protected by composition and method of use patents for AKI respectively and held by Arch Biopartners.

Publication Details

Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver

Authors

Saurav Roy Choudhury, Liane Babes, Jennifer J. Rahn, Bo-Young Ahn, Kimberly-Ann R. Goring, Jennifer C. King, Arthur Lau, Björn Petri, Xiaoguang Hao, Andrew K. Chojnacki, Ajitha Thanabalasuriar, Erin F. McAvoy, Sébastien Tabariès, Christoph Schraeder, Kamala D. Patel, Peter M. Siegel, Karen A. Kopciuk, David C. Schriemer, Daniel A. Muruve, Margaret M. Kelly, Bryan G. Yipp, Paul Kubes, Stephen M. Robbins, Donna L. Senger

Details
Highlights
  • Dipeptidase 1 (DPEP1) serves as a vascular adhesion molecule in lungs and liver
  • DPEP1 acts as a physical adhesion receptor independent of its dipeptidase activity
  • Targeting DPEP1 reduces mortality in murine models of sepsis
Abstract

A hallmark feature of inflammation is the orchestrated recruitment ...

Contact Arch Biopartners
Stay connected!

Subscribe for email updates

Get email alerts when news is published
Please check the options for Investor News and Press releases to receive customized email alerts.

Publications Archives